Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 6

Long-term azithromycin therapy in patients with severe COPD and repeated exacerbations

Authors Pomares X, Montón C, Espasa Soley M, Casabon Salas J, Monsó E, Gallego M

Published 6 September 2011 Volume 2011:6 Pages 449—456


Review by Single-blind

Peer reviewer comments 2

Xavier Pomares1, Concepción Montón1, Mateu Espasa2, Jordi Casabon1, Eduard Monsó1,3, Miguel Gallego1,3
Pneumology Service, 2Laboratory Service, Corporació Parc Taulí, Universitat Autònoma de Barcelona, Sabadell, Spain; 3Ciber de Enfermedades Respiratorias – CibeRes, Bunyola, Spain

Background: The aim of this study was to determine whether long-term intermittent azithromycin therapy reduces the frequency of exacerbation in severe chronic obstructive pulmonary disease (COPD).
Methods: We retrospectively investigated the clinical benefits of long-term azithromycin (500 mg orally three times per week) over 12 months in patients with severe COPD and a minimum of four acute exacerbations (AECOPD) per year or chronic bronchial colonization by Pseudomonas aeruginosa, comparing the number of AECOPD, hospitalizations due to respiratory disease, days of hospital stay, and bacterial infections during azithromycin treatment and in the year prior to this therapy.
Results: Twenty patients who completed the 12-month treatment period were analyzed. No clinically significant adverse events were observed during azithromycin treatment. Compared with baseline data, azithromycin therapy significantly reduced the number of AECOPD (2.8 ± 2.5 versus 6.8 ± 2.8, P < 0.001), hospitalizations (1.4 ± 1.5 versus 3.6 ± 1.4, P < 0.001), and cumulative annual days of hospital stay (25 ± 32.2 versus 43.7 ± 21.4, P = 0.01). The improvement was particularly significant in patients with exacerbations caused by common potentially pathogenic microorganisms, who had 70% fewer AECOPD and hospitalizations. Patients colonized by P. aeruginosa had reductions of 43% in AECOPD and 47% in hospitalizations.
Conclusion: Long-term azithromycin is well tolerated and associated with significant reductions in AECOPD, hospitalizations, and length of hospital stay in patients with severe COPD.

Keywords: azithromycin, chronic obstructive pulmonary disease, exacerbation, macrolides

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]